{"title":"Curating model parameters","markdown":{"yaml":{"title":"Curating model parameters","format":{"revealjs":{"theme":"slides.scss","incremental":true,"slide-number":true,"logo":"../vchem.png","html-math-method":"katex","transition":"fade","background-transition":"fade","highlight-style":"ayu-mirage","footer":"[Back to Website](../index.html)\n"}},"editor_options":{"chunk_output_type":"console"},"editor":"source"},"headingText":"Learning Objectives and Outline","containsRefs":false,"markdown":"\n\n\n## Learning Objectives\n\n-   Classify model parameters across different economic perspectives\n\n-   Characterize the data collection approaches for cost-effectiveness studies (i.e., alongside clinical trials versus secondary data collection)\n\n-   Identify resources and tools for collecting both cost and benefit parameters\n\n## Outline\n\n::: columns\n::: {.column width=\"50%\"}\n1.  ICER review\n2.  Perspective\n3.  Data collection\n:::\n\n::: {.column width=\"50%\"}\n4.  Numerator: Costs\n5.  Denominator: Effects\n:::\n:::\n\n# ICER review {background=\"#43464B\"}\n\n$$\n\\frac{C_1 - C_0 \\quad  (\\Delta C)}{E_1 - E_0 \\quad  (\\Delta E)}\n$$\n\n## Numerator (costs)\n\nValued in monetary terms\n\n<br> - E.g., <br> [\\$USD / ₦NGN / KES / R]{style=\"color: #016301\"}\n\n## Denominator (benefits):\n\nValued in terms of **clinical outcomes**\n\n<br> - E.g., <br> [\\# of HIV cases prevented]{style=\"color: #016301\"} <br> [\\# of children seizure free]{style=\"color: #016301\"} <br> [\\# of quality-adjusted life years gained]{style=\"color: #016301\"} <br>\n\n-   What's important for the question at hand\n-   Most analyses report several different outcomes\n-   QALY/DALYs enable comparability across disease areas\n\n# Perspective matters {background=\"#43464B\"}\n\n::: {style=\"font-size: 0.8em\"}\n## Formal healthcare sector\n\n**Costs:** Medical costs borne by \"third-party payers\" & paid for out-of-pocket by patients <br> **Benefits:** Health impact to patient & if relevant, family/unpaid caregiver <br>\n\n::: incremental\n-   In many countries, this might mean \"donor payers\" and/or largely out-of-pocket costs by patients.\n-   This might also include \"program costs\" paid for by donor of government entities\n-   Ideally, costs from a healthcare sector perspective should include **current + future costs**, related & unrelated to the condition under consideration\n:::\n:::\n\n::: {style=\"font-size: 0.8em\"}\n## Societal perspective\n\nRepresents the wider \"public interest\" & inter-sector distribution of resources that are important to consider <br>\n\n-   Includes patient transportation/travel, non-medical out-of-pocket costs, and time/productivity costs\n-   May include family/informal caregiver costs related to transport/travel, non-medical out-of-pocket costs, time/productivity costs <br>\n\n::: incremental\n-   **Presenteeism** (i.e., lost productivity when individuals are not fully functional at work due to illness)\n-   **Absenteeism** (i.e., time absent from work as a consequence of illness)\n:::\n:::\n\n# Data collection {background=\"#43464B\"}\n\n## Two approaches:\n\n<br> (1) Alongside [**clinical trials**]{style=\"color: #00589b;\"} <br> (2) Using [**secondary data**]{style=\"color: #00589b;\"}\n\n# 1. Data collection alongside [clinical trials]{style=\"color: aquamarine;\"} {background=\"#43464B\"}\n\n::: {style=\"font-size: 0.8em\"}\n## Costs (clinical trials)\n\nSource: Gold 1996, Drummond 2015, Gray 2012) <br>\n\n1.  **Identify** -- Estimate the different categories of resources likely to be required (e.g., surgical staff, medical equipment, surgical complications, re-admissions) <br> <br>\n\n2.  **Measure** -- Estimate how much of each resource category is required (e.g. type of staff performing the surgery and time involved, post-surgery length of stay, re-admission rates) <br> <br>\n\n3.  **Value** -- Apply unit costs to each resource category (e.g., salary scales from the relevant hospital or national wage rates for staff inputs, cost per inpatient day for the post-surgery hospital stay)\n:::\n\n## Costs (clinical trials)\n\n![](images/Screen%20Shot%202022-09-06%20at%2011.08.13%20AM.jpeg)\n\n## Costs (clinical trials)\n\n![](images/Screen%20Shot%202022-09-06%20at%2011.09.38%20AM.png)\n\n## Costs (clinical trials)\n\n![](images/Screen%20Shot%202022-09-06%20at%2011.09.14%20AM.png)\n\n## Effects (clinical trials)\n\n-   Important clinical outcomes of the trial (e.g. cases or deaths averted)\n-   If seeking to measure **QALYs** gained, the EQ-5D (an indirect preference-based weight tool) can be obtained in several different languages\n    -   visit: [euroqol.org/eq-5d-instruments/all-eq-5d-versions/]{style=\"color: blue;\"}\n    -   Age/proxy requirements can also be found on this site\n\n## Effects (clinical trials)\n\nIf seeking to measure **DALYs** averted (DALYs typically utilizes standardized disability weights): <br>\n\n-   **Published Global burden of disease weights** can be used alongside other data points collected in the clinical trial, such as \"age of onset of disease.\"\n\n-   Other data needed to calculate DALYs, such as \"life expectancy\" due to disease/stages of disease, can also be estimated (more on that in the \"secondary data\" section)\n\n## Effects (clinical trials)\n\n<br>\n\n> Since disability weights are freely & publicly available (these weights are required for DALY calculations), it can reduce costs/time/resources compared to collecting QALY estimates\n\n## Productivity/time associated costs (clinical trials)\n\n-   **Productivity (presenteeism & absenteeism)** can be measured with validated instruments such as the [Work Productivity and Activity Impairment Questionnaire (WPAI)]{style=\"color: #016301\"}, among others published <br><br>\n-   Scores from these instruments can be used to estimate the **% of work-related productivity loss**, which can be monetized based on assumptions on population wage and number of hours typically spent working\n\n# 2. Using [secondary]{style=\"color: aquamarine;\"} data only {background=\"#43464B\"}\n\n::: {style=\"font-size: 0.8em\"}\n## Costs (secondary data)\n\n(Same approach as for clinical trials above) <br>\n\n1.  **Identify** -- Estimate the different categories of resources (e.g., surgical staff, medical equipment, surgical complications, re-admissions) <br> <br>\n\n2.  **Measure** -- Estimate how much of each resource category is required (e.g. type of staff performing the surgery and time involved, post-surgery length of stay, re-admission rates) <br> <br>\n\n3.  **Value** -- Apply unit costs to each resource category (e.g., salary scales from the relevant hospital or national wage rates for staff inputs, cost per inpatient day for the post-surgery hospital stay)\n:::\n\n## Costs (secondary data)\n\n1.  **In country/hospital/donor data registries** - key is to get as close to the \"true\" cost associated with each procedure per patient\n    -   E.g., \"TB healthcare & diagnostics are from official price list of the National Health Laboratory Service in South Africa; Costs for follow-up reflect local clinic and culture-based screening for active-tuberculosis\"\n2.  **Review of published literature**\n3.  **Tufts CEA Registry**\n4.  **DCP3: Disease Control Priorities**\n\n## Costs (secondary data)\n\n![](images/file_show-01.jpeg)\n\n## Costs (secondary data)\n\n![](images/1.png)\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-09-06%20at%202.47.32%20PM.jpeg){width=\"766\"}\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-09-06%20at%203.53.38%20PM.png)\n\nhttps://cevr.tuftsmedicalcenter.org/databases/cea-registry\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-10-04%20at%203.24.08%20PM.png){width=\"570\"}\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-10-04%20at%203.53.22%20PM.png)\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-10-04%20at%203.28.14%20PM.png){width=\"529\"}\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-10-04%20at%203.29.14%20PM.png){width=\"499\"}\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-09-06%20at%203.57.05%20PM.png)\n\nhttp://ghcearegistry.org/ghcearegistry/\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-10-04%20at%203.49.19%20PM.png)\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-10-04%20at%203.50.18%20PM.png)\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-09-13%20at%201.41.55%20PM.png){width=\"180\"}\n\n![](images/Screen%20Shot%202022-09-13%20at%201.44.12%20PM.jpeg){width=\"533\"}\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-09-13%20at%201.40.58%20PM.png)\n\n## Costs (secondary data)\n\n-   Up until now, we focused on **Micro costing** (bottom-up) (e.g., for treatment-specific costs); Identifying & measuring each resource utilized and applying unit costs\n\n-   **Gross costing** (top-down) estimates the cost of an event or condition; can capture important downstream costs (e.g., hospitalizations due to \"opioid\" relapse/recurrence)\n\n## Costs (secondary data)\n\n![](images/2.png)\n\n## Effects (secondary data)\n\n-   IHME Disease-specific rates\n-   Global burden of disease \\| Tufts DALY calculator \\|\n-   DCP3\n-   Other literature/RCTs/Meta-analyses/etc. - including Tufts registries that we just reviewed + other!\n\n## Effects (secondary data)\n\n![](images/Screen%20Shot%202022-09-14%20at%209.45.01%20AM.png)\n\n## Effects (secondary data)\n\n![](images/Screen%20Shot%202022-09-13%20at%201.55.26%20PM.png)\n\n(Marx et al 2020)\n\n## Effects (secondary data)\n\n![](images/Screen%20Shot%202022-09-13%20at%201.56.36%20PM.png)\n\n(Marx et al 2020)\n\n## Effects (secondary data)\n\n![](images/Screen%20Shot%202022-09-06%20at%202.48.41%20PM.png){width=\"720\" height=\"144\"}\n\n## Effects (secondary data)\n\n![](images/Screen%20Shot%202022-09-14%20at%209.31.26%20AM.png)\n\nA tool that can convert health outcomes expressed in non-DALY metrics (e.g., cases or deaths averted) into DALYs -- converted DALY measures can then be used to compare cost-effectiveness ratios of interventions across different disease areas (http://ghcearegistry.org/ghcearegistry/)\n\n## Effects (secondary data)\n\n![](images/Screen%20Shot%202022-09-14%20at%209.34.46%20AM.png){width=\"765\"}\n\n## Effects (secondary data)\n\n![](images/DCP1.jpeg){width=\"172\"}\n\n![](images/DCP2.jpeg){width=\"426\"}\n","srcMarkdownNoYaml":"\n\n# Learning Objectives and Outline\n\n## Learning Objectives\n\n-   Classify model parameters across different economic perspectives\n\n-   Characterize the data collection approaches for cost-effectiveness studies (i.e., alongside clinical trials versus secondary data collection)\n\n-   Identify resources and tools for collecting both cost and benefit parameters\n\n## Outline\n\n::: columns\n::: {.column width=\"50%\"}\n1.  ICER review\n2.  Perspective\n3.  Data collection\n:::\n\n::: {.column width=\"50%\"}\n4.  Numerator: Costs\n5.  Denominator: Effects\n:::\n:::\n\n# ICER review {background=\"#43464B\"}\n\n$$\n\\frac{C_1 - C_0 \\quad  (\\Delta C)}{E_1 - E_0 \\quad  (\\Delta E)}\n$$\n\n## Numerator (costs)\n\nValued in monetary terms\n\n<br> - E.g., <br> [\\$USD / ₦NGN / KES / R]{style=\"color: #016301\"}\n\n## Denominator (benefits):\n\nValued in terms of **clinical outcomes**\n\n<br> - E.g., <br> [\\# of HIV cases prevented]{style=\"color: #016301\"} <br> [\\# of children seizure free]{style=\"color: #016301\"} <br> [\\# of quality-adjusted life years gained]{style=\"color: #016301\"} <br>\n\n-   What's important for the question at hand\n-   Most analyses report several different outcomes\n-   QALY/DALYs enable comparability across disease areas\n\n# Perspective matters {background=\"#43464B\"}\n\n::: {style=\"font-size: 0.8em\"}\n## Formal healthcare sector\n\n**Costs:** Medical costs borne by \"third-party payers\" & paid for out-of-pocket by patients <br> **Benefits:** Health impact to patient & if relevant, family/unpaid caregiver <br>\n\n::: incremental\n-   In many countries, this might mean \"donor payers\" and/or largely out-of-pocket costs by patients.\n-   This might also include \"program costs\" paid for by donor of government entities\n-   Ideally, costs from a healthcare sector perspective should include **current + future costs**, related & unrelated to the condition under consideration\n:::\n:::\n\n::: {style=\"font-size: 0.8em\"}\n## Societal perspective\n\nRepresents the wider \"public interest\" & inter-sector distribution of resources that are important to consider <br>\n\n-   Includes patient transportation/travel, non-medical out-of-pocket costs, and time/productivity costs\n-   May include family/informal caregiver costs related to transport/travel, non-medical out-of-pocket costs, time/productivity costs <br>\n\n::: incremental\n-   **Presenteeism** (i.e., lost productivity when individuals are not fully functional at work due to illness)\n-   **Absenteeism** (i.e., time absent from work as a consequence of illness)\n:::\n:::\n\n# Data collection {background=\"#43464B\"}\n\n## Two approaches:\n\n<br> (1) Alongside [**clinical trials**]{style=\"color: #00589b;\"} <br> (2) Using [**secondary data**]{style=\"color: #00589b;\"}\n\n# 1. Data collection alongside [clinical trials]{style=\"color: aquamarine;\"} {background=\"#43464B\"}\n\n::: {style=\"font-size: 0.8em\"}\n## Costs (clinical trials)\n\nSource: Gold 1996, Drummond 2015, Gray 2012) <br>\n\n1.  **Identify** -- Estimate the different categories of resources likely to be required (e.g., surgical staff, medical equipment, surgical complications, re-admissions) <br> <br>\n\n2.  **Measure** -- Estimate how much of each resource category is required (e.g. type of staff performing the surgery and time involved, post-surgery length of stay, re-admission rates) <br> <br>\n\n3.  **Value** -- Apply unit costs to each resource category (e.g., salary scales from the relevant hospital or national wage rates for staff inputs, cost per inpatient day for the post-surgery hospital stay)\n:::\n\n## Costs (clinical trials)\n\n![](images/Screen%20Shot%202022-09-06%20at%2011.08.13%20AM.jpeg)\n\n## Costs (clinical trials)\n\n![](images/Screen%20Shot%202022-09-06%20at%2011.09.38%20AM.png)\n\n## Costs (clinical trials)\n\n![](images/Screen%20Shot%202022-09-06%20at%2011.09.14%20AM.png)\n\n## Effects (clinical trials)\n\n-   Important clinical outcomes of the trial (e.g. cases or deaths averted)\n-   If seeking to measure **QALYs** gained, the EQ-5D (an indirect preference-based weight tool) can be obtained in several different languages\n    -   visit: [euroqol.org/eq-5d-instruments/all-eq-5d-versions/]{style=\"color: blue;\"}\n    -   Age/proxy requirements can also be found on this site\n\n## Effects (clinical trials)\n\nIf seeking to measure **DALYs** averted (DALYs typically utilizes standardized disability weights): <br>\n\n-   **Published Global burden of disease weights** can be used alongside other data points collected in the clinical trial, such as \"age of onset of disease.\"\n\n-   Other data needed to calculate DALYs, such as \"life expectancy\" due to disease/stages of disease, can also be estimated (more on that in the \"secondary data\" section)\n\n## Effects (clinical trials)\n\n<br>\n\n> Since disability weights are freely & publicly available (these weights are required for DALY calculations), it can reduce costs/time/resources compared to collecting QALY estimates\n\n## Productivity/time associated costs (clinical trials)\n\n-   **Productivity (presenteeism & absenteeism)** can be measured with validated instruments such as the [Work Productivity and Activity Impairment Questionnaire (WPAI)]{style=\"color: #016301\"}, among others published <br><br>\n-   Scores from these instruments can be used to estimate the **% of work-related productivity loss**, which can be monetized based on assumptions on population wage and number of hours typically spent working\n\n# 2. Using [secondary]{style=\"color: aquamarine;\"} data only {background=\"#43464B\"}\n\n::: {style=\"font-size: 0.8em\"}\n## Costs (secondary data)\n\n(Same approach as for clinical trials above) <br>\n\n1.  **Identify** -- Estimate the different categories of resources (e.g., surgical staff, medical equipment, surgical complications, re-admissions) <br> <br>\n\n2.  **Measure** -- Estimate how much of each resource category is required (e.g. type of staff performing the surgery and time involved, post-surgery length of stay, re-admission rates) <br> <br>\n\n3.  **Value** -- Apply unit costs to each resource category (e.g., salary scales from the relevant hospital or national wage rates for staff inputs, cost per inpatient day for the post-surgery hospital stay)\n:::\n\n## Costs (secondary data)\n\n1.  **In country/hospital/donor data registries** - key is to get as close to the \"true\" cost associated with each procedure per patient\n    -   E.g., \"TB healthcare & diagnostics are from official price list of the National Health Laboratory Service in South Africa; Costs for follow-up reflect local clinic and culture-based screening for active-tuberculosis\"\n2.  **Review of published literature**\n3.  **Tufts CEA Registry**\n4.  **DCP3: Disease Control Priorities**\n\n## Costs (secondary data)\n\n![](images/file_show-01.jpeg)\n\n## Costs (secondary data)\n\n![](images/1.png)\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-09-06%20at%202.47.32%20PM.jpeg){width=\"766\"}\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-09-06%20at%203.53.38%20PM.png)\n\nhttps://cevr.tuftsmedicalcenter.org/databases/cea-registry\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-10-04%20at%203.24.08%20PM.png){width=\"570\"}\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-10-04%20at%203.53.22%20PM.png)\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-10-04%20at%203.28.14%20PM.png){width=\"529\"}\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-10-04%20at%203.29.14%20PM.png){width=\"499\"}\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-09-06%20at%203.57.05%20PM.png)\n\nhttp://ghcearegistry.org/ghcearegistry/\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-10-04%20at%203.49.19%20PM.png)\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-10-04%20at%203.50.18%20PM.png)\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-09-13%20at%201.41.55%20PM.png){width=\"180\"}\n\n![](images/Screen%20Shot%202022-09-13%20at%201.44.12%20PM.jpeg){width=\"533\"}\n\n## Costs (secondary data)\n\n![](images/Screen%20Shot%202022-09-13%20at%201.40.58%20PM.png)\n\n## Costs (secondary data)\n\n-   Up until now, we focused on **Micro costing** (bottom-up) (e.g., for treatment-specific costs); Identifying & measuring each resource utilized and applying unit costs\n\n-   **Gross costing** (top-down) estimates the cost of an event or condition; can capture important downstream costs (e.g., hospitalizations due to \"opioid\" relapse/recurrence)\n\n## Costs (secondary data)\n\n![](images/2.png)\n\n## Effects (secondary data)\n\n-   IHME Disease-specific rates\n-   Global burden of disease \\| Tufts DALY calculator \\|\n-   DCP3\n-   Other literature/RCTs/Meta-analyses/etc. - including Tufts registries that we just reviewed + other!\n\n## Effects (secondary data)\n\n![](images/Screen%20Shot%202022-09-14%20at%209.45.01%20AM.png)\n\n## Effects (secondary data)\n\n![](images/Screen%20Shot%202022-09-13%20at%201.55.26%20PM.png)\n\n(Marx et al 2020)\n\n## Effects (secondary data)\n\n![](images/Screen%20Shot%202022-09-13%20at%201.56.36%20PM.png)\n\n(Marx et al 2020)\n\n## Effects (secondary data)\n\n![](images/Screen%20Shot%202022-09-06%20at%202.48.41%20PM.png){width=\"720\" height=\"144\"}\n\n## Effects (secondary data)\n\n![](images/Screen%20Shot%202022-09-14%20at%209.31.26%20AM.png)\n\nA tool that can convert health outcomes expressed in non-DALY metrics (e.g., cases or deaths averted) into DALYs -- converted DALY measures can then be used to compare cost-effectiveness ratios of interventions across different disease areas (http://ghcearegistry.org/ghcearegistry/)\n\n## Effects (secondary data)\n\n![](images/Screen%20Shot%202022-09-14%20at%209.34.46%20AM.png){width=\"765\"}\n\n## Effects (secondary data)\n\n![](images/DCP1.jpeg){width=\"172\"}\n\n![](images/DCP2.jpeg){width=\"426\"}\n"},"formats":{"revealjs":{"identifier":{"display-name":"RevealJS","target-format":"revealjs","base-format":"revealjs"},"execute":{"fig-width":10,"fig-height":5,"fig-format":"retina","fig-dpi":96,"df-print":"default","error":false,"eval":true,"cache":null,"freeze":true,"echo":false,"output":true,"warning":false,"include":true,"keep-md":false,"keep-ipynb":false,"ipynb":null,"enabled":null,"daemon":null,"daemon-restart":false,"debug":false,"ipynb-filters":[],"ipynb-shell-interactivity":null,"plotly-connected":true,"engine":"markdown"},"render":{"keep-tex":false,"keep-typ":false,"keep-source":false,"keep-hidden":false,"prefer-html":false,"output-divs":true,"output-ext":"html","fig-align":"default","fig-pos":null,"fig-env":null,"code-fold":"none","code-overflow":"scroll","code-link":false,"code-line-numbers":true,"code-tools":false,"tbl-colwidths":"auto","merge-includes":true,"inline-includes":false,"preserve-yaml":false,"latex-auto-mk":true,"latex-auto-install":true,"latex-clean":true,"latex-min-runs":1,"latex-max-runs":10,"latex-makeindex":"makeindex","latex-makeindex-opts":[],"latex-tlmgr-opts":[],"latex-input-paths":[],"latex-output-dir":null,"link-external-icon":false,"link-external-newwindow":false,"self-contained-math":false,"format-resources":[]},"pandoc":{"standalone":true,"wrap":"none","default-image-extension":"png","html-math-method":"katex","slide-level":2,"to":"revealjs","incremental":true,"highlight-style":"ayu-mirage","output-file":"lec_parameters.html"},"language":{"toc-title-document":"Table of contents","toc-title-website":"On this page","related-formats-title":"Other Formats","related-notebooks-title":"Notebooks","source-notebooks-prefix":"Source","other-links-title":"Other Links","code-links-title":"Code Links","launch-dev-container-title":"Launch Dev Container","launch-binder-title":"Launch Binder","article-notebook-label":"Article Notebook","notebook-preview-download":"Download Notebook","notebook-preview-download-src":"Download Source","notebook-preview-back":"Back to Article","manuscript-meca-bundle":"MECA Bundle","section-title-abstract":"Abstract","section-title-appendices":"Appendices","section-title-footnotes":"Footnotes","section-title-references":"References","section-title-reuse":"Reuse","section-title-copyright":"Copyright","section-title-citation":"Citation","appendix-attribution-cite-as":"For attribution, please cite this work as:","appendix-attribution-bibtex":"BibTeX citation:","appendix-view-license":"View License","title-block-author-single":"Author","title-block-author-plural":"Authors","title-block-affiliation-single":"Affiliation","title-block-affiliation-plural":"Affiliations","title-block-published":"Published","title-block-modified":"Modified","title-block-keywords":"Keywords","callout-tip-title":"Tip","callout-note-title":"Note","callout-warning-title":"Warning","callout-important-title":"Important","callout-caution-title":"Caution","code-summary":"Code","code-tools-menu-caption":"Code","code-tools-show-all-code":"Show All Code","code-tools-hide-all-code":"Hide All Code","code-tools-view-source":"View Source","code-tools-source-code":"Source Code","tools-share":"Share","tools-download":"Download","code-line":"Line","code-lines":"Lines","copy-button-tooltip":"Copy to Clipboard","copy-button-tooltip-success":"Copied!","repo-action-links-edit":"Edit this page","repo-action-links-source":"View source","repo-action-links-issue":"Report an issue","back-to-top":"Back to top","search-no-results-text":"No results","search-matching-documents-text":"matching documents","search-copy-link-title":"Copy link to search","search-hide-matches-text":"Hide additional matches","search-more-match-text":"more match in this document","search-more-matches-text":"more matches in this document","search-clear-button-title":"Clear","search-text-placeholder":"","search-detached-cancel-button-title":"Cancel","search-submit-button-title":"Submit","search-label":"Search","toggle-section":"Toggle section","toggle-sidebar":"Toggle sidebar navigation","toggle-dark-mode":"Toggle dark mode","toggle-reader-mode":"Toggle reader mode","toggle-navigation":"Toggle navigation","crossref-fig-title":"Figure","crossref-tbl-title":"Table","crossref-lst-title":"Listing","crossref-thm-title":"Theorem","crossref-lem-title":"Lemma","crossref-cor-title":"Corollary","crossref-prp-title":"Proposition","crossref-cnj-title":"Conjecture","crossref-def-title":"Definition","crossref-exm-title":"Example","crossref-exr-title":"Exercise","crossref-ch-prefix":"Chapter","crossref-apx-prefix":"Appendix","crossref-sec-prefix":"Section","crossref-eq-prefix":"Equation","crossref-lof-title":"List of Figures","crossref-lot-title":"List of Tables","crossref-lol-title":"List of Listings","environment-proof-title":"Proof","environment-remark-title":"Remark","environment-solution-title":"Solution","listing-page-order-by":"Order By","listing-page-order-by-default":"Default","listing-page-order-by-date-asc":"Oldest","listing-page-order-by-date-desc":"Newest","listing-page-order-by-number-desc":"High to Low","listing-page-order-by-number-asc":"Low to High","listing-page-field-date":"Date","listing-page-field-title":"Title","listing-page-field-description":"Description","listing-page-field-author":"Author","listing-page-field-filename":"File Name","listing-page-field-filemodified":"Modified","listing-page-field-subtitle":"Subtitle","listing-page-field-readingtime":"Reading Time","listing-page-field-wordcount":"Word Count","listing-page-field-categories":"Categories","listing-page-minutes-compact":"{0} min","listing-page-category-all":"All","listing-page-no-matches":"No matching items","listing-page-words":"{0} words","listing-page-filter":"Filter","draft":"Draft"},"metadata":{"lang":"en","fig-responsive":false,"quarto-version":"1.8.24","auto-stretch":true,"title":"Curating model parameters","editor_options":{"chunk_output_type":"console"},"editor":"source","theme":"slides.scss","slideNumber":true,"logo":"../vchem.png","transition":"fade","backgroundTransition":"fade","footer":"[Back to Website](../index.html)\n"}}},"projectFormats":["html"]}